Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study of AB103 as Compared to Placebo in Patients With Necrotizing Soft Tissue Infections. ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Atox Bio Ltd
- 入组人数
- 290
- 试验地点
- 71
- 主要终点
- Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE)
研究概览
简要总结
The purpose of this study is to determine whether AB103 is safe and effective in the treatment of patients with necrotizing soft tissue infections (NSTI) receiving standard of care therapy.
详细描述
The primary hypothesis of this study is that in addition to standard of care treatment (which includes surgical intervention, antimicrobial therapy and critical care support for organ dysfunction or failure), AB103 will demonstrate a clinically significant treatment benefit over placebo.
This hypothesis will be addressed by measuring the effect of AB103 on a composite of clinical parameters associated with the disease course of patients with NSTI, using a responder analysis. A responding patient must meet all 5 parameters of the composite clinical success end point, while a non-responding patient can fail by not meeting any one of the parameters. These analyses are designed to demonstrate that in addition to being safe, one dose of 0.5 mg/kg of AB103 will:
Improve systemic signs of the infection by improving organ function of patients compared to placebo as measured by:
- Survival at Day 28
- Modified SOFA (mSOFA) score on Day 14 and change from baseline to Day 14 ≥ 3. A Day 14 mSOFA score of ≤1 and a change from baseline (pre-treatment) to Day 14 ≥3 will be required for a patient to achieve the primary composite clinical success endpoint (NICCE)
Improve the local signs of the infection, as measured by:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Surgical confirmation of NSTI by attending surgeon;
- •mSOFA score ≥3 (in any one or combination of the 5 major components of SOFA score with one organ component having a score of at least 2: cardiovascular, respiratory, renal, coagulation, CNS), measured as close as possible to the first debridement;
- •IV drug administration within 6 hours from the clinical diagnosis and the decision at the study site, to have an urgent surgical exploration and debridement (drug should not be administered until surgical confirmation is established);
- •If a woman is of childbearing potential, she must consistently use an acceptable method of contraception from baseline through Day 28;
- •If a male patient's sexual partner is of childbearing potential, the male patient must acknowledge that they will consistently use an acceptable method of contraception (defined above) from baseline through Day
- •Signed and dated informed consent (ICF) as defined by the Institutional Review Board (IRB) and, if applicable, California Bill of Rights. If patient is unable to comprehend or sign the ICF, patient's legally acceptable representative may sign the ICF
排除标准
- •Patient who has been operated at least once for the current NSTI infection and had a curative deep tissue debridement;
- •Patients with overt peripheral vascular disease in the involved area ;
- •Diabetic patients with peripheral vascular disease who present with below the ankle infection;
- •Removed deep vein thrombosis (DVT) in area of NSTI as an exclusion criteria
- •Patient with burn wounds;
- •Current condition of: (a) Inability to maintain a mean arterial pressure > 50 mmHg and/or systolic blood pressure > 70 mmHg for at least 1 hour prior to screening despite the presence of vasopressors and IV fluids or (b) a patient with respiratory failure such that an SaO2 of 80% cannot be achieved or (c) a patient with refractory coagulopathy (INR >5) or thrombocytopenia (platelet count <20,000) that does not partially correct with administration of appropriate factors or blood products;
- •Chronic neurological impairment that leads to a neuro mSOFA component ≥2;
- •Recent cerebrovascular accident in the last 3 months;
- •Patients with cardiac arrest requiring cardiopulmonary resuscitation within the past 30 days;
- •Patient is not expected to survive throughout 28 days of study due to underlying medical condition, such as poorly controlled neoplasm;
- •Patient or patient's family are not committed to aggressive management of the patient's condition;
- •Any concurrent medical condition, which in the opinion of the Investigator, may compromise the safety of the patient or the objectives of the study or the patient will not benefit from treatment such as:
- •Congestive heart failure (CHF){ New York Heart Association (NYHA) class III-IV}
- •Severe chronic pulmonary obstructive disease (COPD)
- •Liver dysfunction {Childs-Pugh class C}
- •Immunosuppression (see Appendix F, Section 15.6 for list of excluded immunosuppressive medications)
- •Neutropenia < 1,000 cells/mm3not due to the underlying infection
- •Idiopathic Thrombocytopenia Purpura
- •Receiving or about to receive chemotherapy or biologic anti-cancer treatment although hormonal manipulation therapies for breast and prostate malignancies are permitted
- •Hematological and lymphatic malignancies in the last 5 years;
- •Known HIV infection with CD4 (cluster of differentiation 4) count < 200 cells/mm3 or < 14% of all lymphocytes;
- •Patients with known chronic kidney disease (documented pre-illness creatinine value(s) ≥2.0) or patients receiving renal replacement therapy for chronic kidney disease;
- •Patients that are treated with continuous hemofiltration (e.g. Continuous Veno-Venous Hemofiltration) for acute kidney dysfunction, not due to NSTI, starting prior to study drug administration;
- •Pregnant or lactating women;
- •Previous enrollment in a clinical trial involving investigational drug or a medical device within 30 days;
- •Previous enrollment in this protocol, ATB-202 or the Phase 2 trial of AB103, ATB-201.
研究组 & 干预措施
AB103 0.5 mg/kg
AB103 0.5 mg/kg, IV, single dose
干预措施: AB103 0.5 mg/kg (Drug)
NaCl 0.9%
NaCl 0.9%, IV, single dose
干预措施: NaCl 0.9% (Other)
结局指标
主要结局
Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE)
时间窗: 28 days
NICCE was made up of the following 5 components, all of which had to be met to successfully achieve the primary outcome measure (i.e., a "responder"): (i) Alive at Day 28, (ii) ≤ 3 debridements through Day 14, (iii) No amputation performed after the first debridement, (iv) Day 14 modified Sequential Organ Failure Assessment (mSOFA) score ≤ 1, and (v) Reduction of ≥ 3 mSOFA score points between Baseline and Day 14. This analysis compared responders in the reltecimod group versus responders in the placebo group. Modified Sequential Organ Failure Assessment (mSOFA) total scores range from 0 to 20, with higher scores reflecting a worse clinical status or outcome. An mSOFA total score of 0 or 1 reflects resolution of organ dysfunction/failure.
次要结局
- Number of Patients With One or More Adverse Events (AEs)(28 days)
- Number of Patients With One or More Serious Adverse Events (SAEs)(28 days)
- Vasopressor-free Days(28 days)
- Number of Patients With One or More Secondary Infections(28 days)
- Number of Patients Achieving Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Score of 0 or 1(14 days)
- Intensive Care Unit (ICU)-Free Days(28 days)
- Ventilator-free Days(28 days)
- Hospital Days(90 days or until end of follow up)
- Number of Patients With a More Favorable or Less Favorable Hospital Discharge Location(90 days)